Who
Charles F. Wagner Jr.
Director
Company insider
Files Form 4 as: Director, TJX Companies; EVP, Co & Fo, Vertex Pharmaceuticals; EVP & Chief Financial Officer, Bruker; EVP Finance & Admin and CFO, Progress Software; Vice President, Millipore Corp /ma.
In numbers
- Trades disclosed
- 207
- Buys
- 0
- Sells
- 21
- Bought
- $0
- Sold
- $30.3M
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 14 Feb 2006
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —636.87 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —26.5 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —636.87 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —636.87 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —26.5 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —636.87 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —26.5 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TJX TJX Companiesoption or derivative · Retail — Specialty | SEC FORM 4 Code A | —26.5 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $846K1,744 at $485.11 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $846K1,744 at $485.11 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,365 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.1M2,294 at $483.75 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,365 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.1M2,294 at $483.75 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $2.2M4,565 at $487.76 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $2.2M4,565 at $487.76 | filing |
| 10 Feb 2026filed 12 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M3,045 at $468.41 | filing |
| 10 Feb 2026filed 12 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M3,045 at $468.41 | filing |
| 22 Jan 2026filed 26 Jan 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —9,440 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,160 at $0.00 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Charles F. Wagner Jr.; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.